Clinical TrialJun 11, 2026, 07:31 AM
Medicus Pharma Submits IND for Phase 2a Endometriosis Trial
AI Summary
Medicus Pharma Ltd. announced the submission of an Investigational New Drug (IND) application to the Department of Health, Abu Dhabi, for PRECISION-E2, a Phase 2a genomics-enabled clinical trial. This study will evaluate Teverelix® in approximately 84 women with symptomatic endometriosis in the United Arab Emirates, leveraging the Emirati Genome Program. The trial aims to develop a personalized treatment model for endometriosis by combining clinical, hormonal, pharmacokinetic, and genomic data, potentially transforming the management of estrogen-driven diseases.
Key Highlights
- Medicus Pharma submitted an IND for PRECISION-E2 Phase 2a clinical trial.
- Trial evaluates Teverelix® for symptomatic endometriosis in the UAE.
- Study will enroll approximately 84 participants across multiple sites.
- PRECISION-E2 is a genomics-enabled trial leveraging Emirati Genome Program.
- Teverelix® is a novel long-acting GnRH antagonist.
- Endometriosis affects approximately one in ten women worldwide.
- Teverelix® has potential ~$6 billion annual market opportunity for other indications.
- SkinJect® has potential ~$2 billion annual market opportunity.
Price Impact
More from MDCX